Mustang Bio Inc (MBIO)

$0.1791

-0.02

(-10.98%)▲

Market is closed - opens 7 PM, 04 Jun 2024

Insights on Mustang Bio Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 169.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 334.8%

Performance

  • $0.17
    $0.19
    $0.18
    downward going graph

    3.86%

    Downside

    Day's Volatility :10.8%

    Upside

    7.22%

    downward going graph
  • $0.16
    $8.17
    $0.18
    downward going graph

    11.11%

    Downside

    52 Weeks Volatility :98.04%

    Upside

    97.8%

    downward going graph

Returns

PeriodMustang Bio IncIndex (Russel 2000)
3 Months
-86.73%
0.0%
6 Months
-87.65%
0.0%
1 Year
-97.05%
0.0%
3 Years
-99.66%
-22.6%

Highlights

Market Capitalization
2.2M
Book Value
- $0.48
Earnings Per Share (EPS)
-4.37
Wall Street Target Price
10.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-56.17%
Return On Equity TTM
-322.45%
Revenue TTM
-50.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-38.2M
Diluted Eps TTM
-4.37
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.57
EPS Estimate Next Year
-5.04
EPS Estimate Current Quarter
-0.87
EPS Estimate Next Quarter
-0.88

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Mustang Bio Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 5483.47%

Current $0.18
Target $10.00

Technicals Summary

Sell

Neutral

Buy

Mustang Bio Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Mustang Bio Inc
Mustang Bio Inc
-40.5%
-87.65%
-97.05%
-99.66%
-99.65%
Moderna, Inc.
Moderna, Inc.
21.03%
85.08%
14.68%
-28.27%
659.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.22%
20.18%
31.88%
93.3%
227.58%
Novo Nordisk A/s
Novo Nordisk A/s
8.85%
34.38%
71.83%
235.07%
463.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
16.81%
34.1%
40.6%
123.97%
174.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Mustang Bio Inc
Mustang Bio Inc
NA
NA
NA
-3.57
-3.22
-0.56
NA
-0.48
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.89
28.89
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.97
46.97
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.59
29.59
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Mustang Bio Inc
Mustang Bio Inc
Buy
$2.2M
-99.65%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.6B
659.22%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
227.58%
28.89
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.6B
463.44%
46.97
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
174.53%
29.59
39.46%

Institutional Holdings

  • Armistice Capital, LLC

    2.02%

  • Vanguard Group Inc

    1.98%

  • BlackRock Inc

    0.97%

  • Koss-Olinger Consulting, LLC

    0.93%

  • Geode Capital Management, LLC

    0.48%

  • Susquehanna International Group, LLP

    0.41%

Company Information

mustang bio, inc., a subsidiary of fortress biotech, inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient’s own immune system to eliminate cancer cells. mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. mustang has partnered with the city of hope national medical center (“coh”) and fred hutchinson cancer research center in the development of proprietary chimeric antigen receptor (car) engineered t cell (car t) therapies across many cancers. mustang’s lead programs are in phase 1 clinical trials at coh: mb-101 for the treatment of brain cancer and mb-102 as a therapeutic agent in acute myeloid leukemia.

Organization
Mustang Bio Inc
Employees
80
CEO
Mr. Michael S. Weiss Esq.
Industry
Health Technology

Discover More

FAQs